Ptc Therapeutics (PTCT) Non-Current Deferred Tax Liability (2018 - 2024)
Ptc Therapeutics (PTCT) has 7 years of Non-Current Deferred Tax Liability data on record, last reported at $55.9 million in Q3 2024.
- For Q3 2024, Non-Current Deferred Tax Liability rose 7.67% year-over-year to $55.9 million; the TTM value through Sep 2024 reached $55.9 million, up 7.67%, while the annual FY2023 figure was $55.9 million, 45.64% down from the prior year.
- Non-Current Deferred Tax Liability reached $55.9 million in Q3 2024 per PTCT's latest filing, roughly flat from $55.9 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $137.1 million in Q4 2021 and bottomed at $51.9 million in Q3 2023.
- Average Non-Current Deferred Tax Liability over 5 years is $106.4 million, with a median of $130.9 million recorded in 2020.
- Peak YoY movement for Non-Current Deferred Tax Liability: crashed 62.13% in 2023, then rose 7.67% in 2024.
- A 5-year view of Non-Current Deferred Tax Liability shows it stood at $136.7 million in 2020, then rose by 0.27% to $137.1 million in 2021, then fell by 25.0% to $102.8 million in 2022, then plummeted by 45.64% to $55.9 million in 2023, then rose by 0.01% to $55.9 million in 2024.
- Per Business Quant database, its latest 3 readings for Non-Current Deferred Tax Liability were $55.9 million in Q3 2024, $55.9 million in Q2 2024, and $55.9 million in Q1 2024.